Local Oestrogen for Perimenopause: Treating GSM with Vaginal Oestrogen
A guide to vaginal local oestrogen for GSM in perimenopause. Covers pessaries, creams and rings, safety for breast cancer survivors, and long-term use.
What Is Genitourinary Syndrome of Menopause?
Genitourinary syndrome of menopause (GSM) is the umbrella term for the constellation of symptoms that arise from oestrogen deficiency in the vaginal, vulval, and urinary tissues. Previously called vulvovaginal atrophy or atrophic vaginitis, the term GSM better captures the breadth of the condition. Oestrogen is essential for maintaining the thickness, elasticity, and moisture of vaginal tissues. As oestrogen declines during perimenopause and after menopause, these tissues gradually thin, lose their natural secretions, and become more fragile and prone to irritation. The symptoms of GSM can include vaginal dryness, itching, burning, soreness, and discomfort or pain during sexual intercourse (dyspareunia). On the urinary side, the same oestrogen depletion affects the urethra and bladder trigone, leading to urinary urgency, frequency, recurrent urinary tract infections, and stress incontinence. GSM affects a significant majority of post-menopausal women to some degree, and unlike vasomotor symptoms such as hot flashes, it tends to worsen progressively over time without treatment rather than improving spontaneously. Understanding this progressive nature is one reason early treatment is recommended rather than waiting until symptoms are severe.
How Local Oestrogen Works and Why It Is Different from Systemic HRT
Local oestrogen preparations are designed to deliver oestrogen directly to the vaginal and vulval tissues without producing significant levels in the bloodstream. This is the defining feature that distinguishes them from systemic HRT. When oestrogen is applied topically to the vagina or vulva in the low doses used for GSM treatment, it is absorbed locally and acts on the oestrogen receptors in those tissues, restoring thickness, lubrication, and elasticity. Very little oestrogen enters the general circulation at standard doses, meaning there is minimal systemic hormonal exposure. This is why local oestrogen is considered safe for women who cannot use systemic HRT, including many breast cancer survivors. Systemic HRT also helps GSM, but it works via circulating oestrogen reaching the tissues. Local oestrogen is specifically targeted and is appropriate as a standalone treatment for women whose main concern is vaginal or urinary symptoms, and as an adjunct to systemic HRT for women who need both menopausal symptom management and local GSM treatment. The two can be used together safely. Local oestrogen does not count as systemic HRT and does not require a progestogen to protect the uterine lining because the blood levels achieved are too low to stimulate the endometrium.
Available Formulations: Pessaries, Creams, Gels and the Ring
Local oestrogen is available in several formulations, each with slightly different characteristics, and the best choice depends on individual preference and the pattern of symptoms. Vaginal pessaries (small tablet-like inserts placed in the vagina) are among the most commonly used. Vagifem and its generic equivalent Vagirux are oestradiol 10 mcg pessaries applied daily for two weeks and then twice weekly as maintenance. They are discrete, easy to use with the applicator provided, and well tolerated. Vaginal cream, such as Ovestin (oestriol cream) or Premarin (conjugated oestrogen cream), is applied using a small applicator and allows more flexibility in application to the vaginal entrance and vulval tissues as well as inside the vagina. Creams can be particularly helpful for women with vulval symptoms such as dryness and soreness that extend beyond the vaginal canal. Vaginal gel (Blissel) is a more recent formulation that some women find more comfortable than cream. The vaginal ring (Estring) is a soft silicone ring inserted into the vagina and left in place for 90 days, releasing a constant low dose of oestradiol. It is convenient for women who prefer not to use daily or twice-weekly applications and is largely unnoticeable once in place. All formulations are effective; the choice comes down to lifestyle, comfort, and the distribution of symptoms.
Safety for Breast Cancer Survivors
One of the most clinically significant aspects of local oestrogen is its safety profile for women with a history of breast cancer. Many women are told after breast cancer treatment to avoid all hormonal therapies, but guidance has evolved considerably. The Royal College of Obstetricians and Gynaecologists (RCOG), NICE, and international menopause societies have all recognised that low-dose local vaginal oestrogen does not meaningfully raise blood oestrogen levels and is therefore unlikely to carry the same risks as systemic oestrogen. GSM can be severely debilitating for breast cancer survivors, many of whom are on aromatase inhibitors that drive oestrogen levels to near zero and dramatically accelerate vaginal atrophy. For these women, local oestrogen at low doses, combined with non-hormonal lubricants and moisturisers, is an important treatment option. Oestradiol pessaries (10 mcg) are the preferred choice because they achieve the lowest systemic absorption. Oestriol preparations may also have a favourable profile. Women on aromatase inhibitors should discuss local oestrogen use with their oncologist, as some clinicians remain cautious. Most oncology centres now permit low-dose local oestrogen for GSM when the quality of life impact is significant, though individual clinical judgement applies.
Long-Term Use and What to Expect
Local oestrogen is designed for long-term use. GSM is a chronic condition that worsens progressively without ongoing treatment, and most women need to continue local oestrogen indefinitely to maintain the benefits. The good news is that long-term use at low doses is well supported by evidence. There is no arbitrary time limit on local oestrogen therapy; NICE and the British Menopause Society both support continued use as long as symptoms warrant it. Initial improvements typically take four to twelve weeks to become noticeable. Dryness and lubrication often improve first, followed gradually by reductions in soreness, improved tissue thickness, and easier sexual intercourse. Urinary symptoms can take longer to respond, up to three to six months in some cases, as urethral tissue restoration is slower. Some women notice that their symptoms return within a few weeks if they stop local oestrogen, which reinforces the importance of maintaining a maintenance schedule (usually twice weekly) rather than using it only when symptomatic. Regular use at maintenance frequency sustains the tissue changes. Women using the vaginal ring replace it every 90 days as a routine. Side effects of local oestrogen at correct doses are rare; mild local irritation can occur initially but usually settles within a few weeks as the tissues adjust.
Combining Local Oestrogen with Non-Hormonal Vaginal Products
Local oestrogen works best as part of a broader approach to vulvovaginal health rather than in isolation. Regular use of a vaginal moisturiser, distinct from a lubricant, is an important adjunct. Vaginal moisturisers such as Replens, YES VM (water-based or oil-based), or hyaluronic acid-based preparations are applied two to three times per week and help maintain baseline vaginal moisture between oestrogen applications. They are non-hormonal and suitable for all women, including breast cancer survivors who cannot use any oestrogen. Lubricants are used immediately before and during sexual activity to reduce friction and discomfort. Water-based lubricants are compatible with all contraceptives; oil-based lubricants should not be used with latex condoms or the Estring ring. Combining regular vaginal moisturiser use with twice-weekly local oestrogen applications produces better outcomes than either alone for most women with moderate to severe GSM. Gentle moisturising of the vulval skin with an unperfumed emollient such as Cetraben or coconut oil also supports tissue health. Avoiding soap, bubble bath, and scented products on vulval tissue is important regardless of HRT or local oestrogen use, as these products disrupt the delicate vaginal microbiome and can exacerbate symptoms.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.